Introduction

Chromium (Cr) and its compounds are widely used in many industries such as chrome manufacturing, chrome plating, ferrochrome production and stainless steel welding. Chromium can also be found in the environment in the form of airborne particles from automobile catalytic converters. Hexavalent chromium [Cr(VI)] is one of two major forms of Cr, and it is recognized as a human carcinogen. It is estimated that tens of millions of people are exposed to chromium worldwide [1]. Epidemiological and risk assessment studies have indicated that inhalation exposure to Cr (VI) significantly increases the risk of respiratory cancer, especially lung cancer, in workers [2]. There are three well-accepted general carcinogenic paradigms which include multistage carcinogenesis, genomic instability and epigenetic modifications [3]. Since epigenetics was first introduced by Conrad Waddington in 1942, people are paying more and more attention to it, which plays a significant role in phenotypic expression. Epigenetic modifications are heritable changes in gene expression that occur without changes in DNA sequences [4], and DNA methylation is one of the most common and best understood epigenetic mechanisms [5]. Global DNA hypomethylation is generally associated with chromosomal instability, and hypermethylation at promoter of specific gene may silence the expression of this gene [6].

Some in-vivo and human investigations about Cr (VI)-induced DNA methylation have been conducted/carryed out so far. It was reported that exposure to potassium chromate was able to induce promoter methylation of gpt transgene in Chinese hamster G12 lung cells [7]. A study about genetic and DNA methylation changes in Brassica napus L. plants showed that potassium dichromate induced genome-wide DNA hypermethylation in the CCGG-sequence and the effect was dose-dependent [8]. Meanwhile, methylation of p16 gene has been frequently found in chromate lung cancers [9,10]. More interestingly, Kondo et al. [10] found that more than 80% of the chromate lung cancers showed repression of the p16 protein. Therefore, it was suggested that methylation of p16 was closely associated with chromate lung cancers, but the question is whether the methylation of p16 is the cause of chromate lung cancer, or just the consequence of cancer? p16 is located on chromosomal arm 9p and is a tumor suppressor gene. The product of p16 gene is an inhibitor of CDK 4/6, which phosphorylates the serine/threonine residues of the tumor suppressor gene. The product of p16 gene is an inhibitor of CDK 4/6, which phosphorylates the serine/threonine residues of the tumor suppressor gene. The product of p16 gene is an inhibitor of CDK 4/6, which phosphorylates the serine/threonine residues of the tumor suppressor gene. The product of p16 gene is an inhibitor of CDK 4/6, which phosphorylates the serine/threonine residues of the tumor suppressor gene. The product of p16 gene is an inhibitor of CDK 4/6, which phosphorylates the serine/threonine residues of the tumor suppressor gene. The product of p16 gene is an inhibitor of CDK 4/6, which phosphorylates the serine/threonine residues of the tumor suppressor gene. The product of p16 gene is an inhibitor of CDK 4/6, which phosphorylates the serine/threonine residues of the tumor suppressor gene. The product of p16 gene is an inhibitor of CDK 4/6, which phosphorylates the serine/threonine residues of the tumor suppressor gene. The product of p16 gene is an inhibitor of CDK 4/6, which phosphorylates the serine/threonine residues of the tumor suppressor gene. The product of p16 gene is an inhibitor of CDK 4/6, which phosphorylates the serine/threonine residues of the tumor suppressor gene. The product of p16 gene is an inhibitor of CDK 4/6, which phosphorylates the serine/threonine residues of the tumor suppressor gene.

Previous studies indicated that Cr (VI) could cause cell cycle arrest in HeLa cells, human lung epithelial A549 cells, human lymphoma L929 cells, p53 mutated cells [11], human lung epithelial H460 cells and primary human lung IMR90 fibroblasts [12]. Stanley et al. [13] reported that Cr (VI) could arrest cell cycle...
by down-regulating cyclin-dependent kinases (CDK4, CDK6, CDK1) and up-regulating CDK-inhibitor (p16) in both primary and immortalized granulosa cells from rats. But no study has been performed in human lymphocytes or related cell lines, and the mechanism of up-regulating p16 gene remains unclear. Also few study compared the difference of cell cycle arresting effects and the underlying mechanisms between soluble and particulate Cr (VI). Although both soluble and particulate Cr (VI) are cytotoxic and genotoxic to human lung epithelial cells [14], and human and sperm whale skin cells [15], the effects of these two types of chromate on methylation status of p16 gene in a transgenic Chinese hamster lung cell line with a bacterial gpt reporter gene were different. Partial methylation in the gpt gene was found after soluble Cr (VI) exposure, but no methylation changes after particulate Cr (VI) exposure [7].

In the present study, a human B lymphoblastoid cell line and a human lung cell line A549 were exposed to different concentrations of soluble (K2Cr2O7) or particulate (PbCrO4) chromate. Cell cycle progression and cell cycle regulatory gene expressions were analyzed in samples treated with Cr (VI), and the global DNA methylation level and methylation status of p16 gene were also detected. The aim of our study is to investigate the relationship between DNA methylation and cell cycle progression, and to compare the difference of cell cycle arresting effects and its possible mechanisms between soluble and particulate Cr (VI).

**Materials and Methods**

**Cell Culture and Treatments**

Human B lymphoblastoid cell line was purchased from Cell Bank, Chinese Academy of Sciences, and it was cultured in IMDM (HyClone, USA) supplemented with 10% fetal bovine serum (HyClone, USA). A549, a human lung cell line, was kindly provided by Professor Z. Y. Jia (Zhejiang Academy of Medical Sciences, P. R. CHINA) and cultured in RPMI-1640 supplemented with 10% fetal bovine serum (HyClone, USA). Cells were maintained at 37°C in a fully humidified atmosphere with 5% CO2, and they were subcultured every 2–3 days.

Cells were exposed to potassium dichromate (K2Cr2O7, Sigma, USA) or lead chromate (PbCrO4, Sigma,USA). The concentration of potassium dichromate was 0 μM, 5.0 μM, 10 μM, and 15 μM, and the concentrations of lead chromate were 0 μg/cm², 1.25 μg/cm², 2.5 μg/cm², and 5 μg/cm². The exposure time was 2 hours or 24 hours for potassium dichromate, and 4 hours or 24 hours for lead chromate. Solutions of potassium dichromate were prepared by dissolving it in double distilled water, and then sterilized through a 10 ml syringe with a 0.2 μm filter. Suspension of lead chromate were made according to descriptions by Wise et al. [14].

**Cell Cycle Analysis**

Cells treated with potassium dichromate or lead chromate were collected, rinsed twice with cold PBS, and then fixed in ice cold 70% ethanol and kept at 4°C overnight. Subsequently, the cells were treated with DNase-free RNase and stained with propidium iodide in staining buffer using Cell Cycle Analysis Kit (Byotime, China) for 30 minutes at 37°C. The number of cells distributed in G1, S, and G2-M phases of the cell cycle was counted on a flow cytometer (BD, USA) using Cell Quest software.

**Total RNA Extraction**

Total RNA was extracted from cells using Trizol® reagent (Invitrogen, USA) according to manufacturer’s protocols. The purity and concentrations of extracted RNA were determined by a NanoDrop 2000 (Thermo Scientific, USA) spectrophotometer.

**DNA Extraction and Bisulfite Modification**

DNA was extracted from cells using DNA extraction Kit for cells and tissues (OMEGA BioTek, USA) following the manufacturer’s protocols. DNA from each sample was treated with sodium bisulfite using the EZ DNA Methylation-Gold™ Kit (Zymo Research, Orange, USA) according to manufacturer’s protocol.

**Detection of Global Methylation Patterns**

MethylFlash™Methylated DNA Quantification Kit (Epigen-tek, Brooklyn, USA) was used for detecting global methylation status of the DNA isolated from Cr (VI) treated samples. All procedures were carried out according to manufacturer’s protocol. To determine the relative methylation status of two different DNA samples, simple calculation for percentage of 5-methylcytosine (5-MC) in total DNA can be carried out using the following formula:

\[
5-MC% = \frac{(\text{SampleRFU} - \text{MF3RFU}) + S}{(\text{MF4RFU} - \text{MF3RFU}) \times 2^* + P} \times 100\%
\]

S is the amount of input sample DNA in ng, P is the amount of input positive control (MF4) in ng, MF3 = negative control, RFU = relative fluorescence units.

**Methylation Specific PCR (MSP)**

The methylation status of the promoter of the p16 gene was determined by MSP according to the description of Kondo et al. [10]. The primer sequences for detecting the methylated p16 gene were 5’-TTATTAGAGGGTGCGGATCGG-3’ (forward) and 5’-GCCCCCGAACCGACCTGTA-3’ (reverse), which amplified a 150 bp product. The primer sequences for the unmethylated reaction were 5’-TTATTAGAGGGTGCGGATCGG-3’ (forward) and 5’-CCACCTTAAATCAACCTCGAACC-3’, giving an amplification product of 234 bp. MSP amplification for the p16 gene was carried out in a final volume of 25 μl, 12.5 μl Zymo Taq™ PreMix, 1.2 μl primers, 2 μl DNA template, 9.5 μl ddH2O. Amplification was performed in a PTC-200 DNA Engine Thermal Cycler machine (Bio-Red, USA). The PCR conditions for MSP were as follows: hot start at 95°C for 10 min; then 35 cycles (30s at 95°C for denaturation, 30s at 68°C (methylated gene) or 64°C (unmethylated gene) for annealing, 50s at 72°C for elongation followed by 5min at 72°C for extension. The methylated (M) and unmethylated (U) control DNA (Qiagen, Germany) were used as a positive control for the methylated and unmethylated p16 gene, respectively. Five microliter of each PCR reaction was directly loaded onto a 3% agarose gel, stained with GelRed™ Nucleic Acid Gel Stain (Biotium, USA) and visualized under UV illumination using the Alpha Innotech FluorChem FC2 Imager (Alpha Innotech, USA) to determine if there is a visible band and discriminate the size of the PCR products according to bands of the marker.

**Primer Design and Pyrosequencing**

Primers were designed by using the PSQ assay design program (Biotage, Charlotte, NC, USA). The primer sequences of p16 were 5’-AGGGGTGGTTGTGGTTATAG-3’ (forward) and 5’-biotin-CTCACCTACTCTCCCCCTGC-3’ (reverse) for PCR amplifying a part of CPG islands, and 5’-GTTGTGGTTATAGGAGGT-3’ for pyrosequencing. PCR reaction was performed in a volume of 25 μl with 1.5 μl converted gDNA, 12.5 μl Taq™ PreMix (CoWin, Beijing, China), 0.8 μl primers, 10.2 μl ddH2O.
The amplification condition was as following: denaturing at 95 °C for 10 minutes, followed by 45 cycles at 95 °C for 30 seconds, at 58 °C (B cells) or 62 °C (A549 cells) for 40 seconds, at 72 °C for 30 seconds and a final extension at 72 °C for 10 minutes. Confirmation of PCR product quality was established on 1.5% agarose gel stained with GelRed. Pyrosequencing was performed using the PyroMark Q24 System (Qiagen, Germany) according to manufacturer’s instructions.

**mRNA Quantification by Real-time Quantitative PCR (RT-qPCR)**

First-strand cDNA was synthesized by reverse transcription of total RNA with PrimeScript™ RT reagent Kit (TaKaRa, China). Quantitative PCR was performed in triplicate per sample for each gene using the SYBR Green PCR system (SYBR Premix Ex Taq™, TaKaRa, China) under the following conditions: 95 °C for 1 minute and immediately repetitively cycled 40 cycles times through a denaturizing step at 95 °C for 30 seconds and an annealing-elongation step at 64 °C (p16 and CDK6) or 60 °C (GAPDH) for 20s. The primer sequences were as follows: p16 5'-GGCACCAGAGGCGTAAACCA-3' (forward) and 5'-CTCTGAGTCCTGTTCTTC-TAGA-3', (reverse), CDK6 5'-GTGACCAAGCGGCGACAAA-TAA-3' (forward) and 5'-AGCAAGACTTCCGGTTGCTCTGTA-3' (reverse), CDK4 5'-TTTCTGAGTCCAGATATGGAACA-3' (forward) and 5'-GGTGCGCCTGGAGTTCCAC-3' (reverse), and GAPDH 5'-GAAGATGGTGATGGGATTTCGAA-3' (forward) and 5'-GAAGATGGTGATGGGATTTCGAA-3' (reverse). Relative fold change was determined using the comparative Ct method using GAPDH as endogenous control [16].

**Western Blot**

Total cell lysates were resolved by SDS-PAGE and transferred to PVDF membranes (Millipore, Billerica, USA), and membranes were blocked and incubated with primary antibodies against p16 (Epitomics, California, USA) and tublin (Huabio, Hangzhou, China) at 4 °C overnight. Antibody binding was detected with horseradish peroxidase-conjugated antibodies (Huabio, Hangzhou, China) and enhanced chemiluminescence (Millipore, Billerica, USA). Reactive bands were analyzed using Image-Pro Plus program (Media Cybernetics, Inc, USA), and the target protein expression was normalized with respect to tublin expression.

**Statistical Analyses**

One-way ANOVA was used to compare the effects among various treatment groups. Where significant differences were found, Dunnett’s multiple comparison test (equal variances not assumed) or LSD (equal variances assumed) was applied to make post hoc comparison between the means of controls and treatments. Differences were considered significant at $P<0.05$ for two-tailed tests. Statistical analysis was performed with SPSS 11.0 for windows.

**Results**

**Cell Cycle Arrest Induced by Cr (VI)**

The effects of Cr (VI) on cell cycle were determined in human B lymphoblastoid cells. In 24 hours exposure group, the percentages of G1-phase cells in samples treated with K$_2$Cr$_2$O$_7$ (Fig. 1-B) increased significantly ($P<0.01$) in a concentration dependent manner, and the percentages of G$_1$-phase cells in samples treated with PbCrO$_4$ were also significantly ($P<0.01$) higher than those in controls (Fig. 1-D). Conversely, the percentages of S-phase cells in samples treated with soluble or particulate chromium were significantly ($P<0.05$, $P<0.01$) lower than those in controls. No significant ($P>0.05$) changes of the percentages of G$_2$-phase cells were observed in both soluble and particulate chromium treatment groups (Fig. 1-B, D). In 2-hour or 4-hour exposure group, significant change was only observed in the percentages of S-phase cells in samples exposed to 5 μg/cm$^2$ PbCrO$_4$, which was significantly ($P>0.05$) higher than those in controls (Fig. 1-C).

The effects of Cr (VI) on cell cycle of A549 cells were similar to those of human B lymphoblastoid cells, but there were also some differences between these two cell lines. No significant ($P>0.05$) change of cell cycle of A549 cells was observed in short-term (2 hours or 4 hours) exposure group (Fig. 1-E, G). Cells were significantly ($P<0.05$, $P<0.01$) arrested at G1 phase by both chromium compounds, and the percentages of G2/M-phase cells decreased significantly ($P<0.05$, $P<0.01$) (Fig. 1-F, H).

**Global Hypomethylation Induced by Cr (VI)**

Global methylation status was analyzed by measuring the percentage of 5-mC in total DNA from cells treated with Cr (VI), and the change of global methylation in both cell lines was similar. The global methylation levels of DNA samples from these two cell lines without treatment were below 0.3% (Fig. 2). Both K$_2$Cr$_2$O$_7$ and PbCrO$_4$ could decrease the percentages of 5-mC in total DNA in a concentration dependent manner. Significant ($P<0.01$) decrease of global methylation levels were observed at all concentrations of both two chromate compounds, compared with that of controls, except of 5 μM of K$_2$Cr$_2$O$_7$ (Fig. 2). In human B lymphoblastoid cells, the decrease of global methylation levels was more obvious in short-term (2 or 4 hours) exposure groups than those in long-term (24 hours) exposure groups, but it was not so obvious in A549 cells.

**DNA Methylation Status at the Promoter of p16 gene**

The DNA methylation status of p16 was qualitatively determined with MSP. Our results indicated that the promoter of p16 gene in both cell lines was completely methylated, and neither K$_2$Cr$_2$O$_7$ nor PbCrO$_4$ could reduce the methylation level of p16 gene, even at the highest concentrations (Fig. 3). To further quantitatively analyze the effect of Cr (VI) on the methylation of p16 gene, pyrosequencing was performed after PCR amplification. The results were consistent with that of MSP, and the percentages of methylation at the promoter of p16 gene were higher than 94% in all samples treated with Cr (VI) and controls (Fig. 4).

**Cr (VI) Up-regulated mRNA level of p16**

Real-time quantitative PCR was utilized to assess the effects of Cr (VI) on mRNA expression of p16 gene. In the K$_2$Cr$_2$O$_7$ exposure group, no significant ($P>0.05$) change was observed after 2 hours exposure, but mRNA levels of p16 in human B lymphoblastoid cells increased significantly ($P<0.01$) in a concentration dependent manner when exposure time was extended to 24 hours (Fig. 5-A), and significant ($P<0.01$) increase was only observed at moderate and high exposure groups in A549 cells (Fig. 5-C). In the PbCrO$_4$ exposure group, no significant ($P>0.05$) difference of mRNA levels of p16 was found between samples treated with PbCrO$_4$ for 4 hours and controls. Significant change of mRNA levels of p16 in human B lymphoblastoid cells was only observed at 2.5 μg/cm$^2$ of PbCrO$_4$ after 24 hours exposure (Fig. 5-B), and significant ($P<0.01$) increase was found at moderate and high exposure groups in A549 cells (Fig. 5-D).
Figure 1. Cr (VI)-induced cell cycle arrest in two cell lines. The concentrations of potassium dichromate were 0, 5 μM, 10 μM, and 15 μM, and the concentrations of lead chromate were 0, 1.25 μg/cm², 2.5 μg/cm², and 5.0 μg/cm². A–B: Percentages of human B lymphoblastoid cells at G₁, S, and G₂ phases after being exposed to potassium dichromate for 2 hours (A) and 24 hours (B). C–D: Percentages of human B lymphoblastoid cells at G₁, S, and G₂ phases after being exposed to lead chromate for 4 hours (C) and 24 hours (D). E–F: Percentages of A549 cells at G₁, S, and G₂ phases after being exposed to potassium dichromate for 2 hours (E) and 24 hours (F). G–H: Percentages of A549 cells at G₁, S, and G₂ phases after being exposed to lead chromate for 4 hours (G) and 24 hours (H). Hash keys above the bars: $P<0.05$ as compared with control; asterisks above the bars: $P<0.01$ as compared with control.
doi:10.1371/journal.pone.0071031.g001

Figure 2. Global hypomethylation induced by Cr (VI) in two cell lines. A and C: Percentages of 5-methyl-cytosine (5-mC) in DNA extracted from human B lymphoblastoid cells (A) and from A549 cells (C) treated with potassium dichromate for 2 hours and 24 hours. B and D: Percentages of 5-methyl-cytosine (5-mC) in DNA extracted from human B lymphoblastoid cells (B) and from A549 cells (D) treated with lead chromate for 4 hours and 24 hours. Asterisks above the bars indicate that the difference between exposure and control was significant ($P<0.01$).
doi:10.1371/journal.pone.0071031.g002
The mRNA expression of CDK4 gene in both cell lines was significantly repressed by 5–15 μM of K₂Cr₂O₇ in 24-hour exposure groups ($p<0.05$, $p<0.01$), and no significant expression change was observed in 2-hour exposure groups (Fig. 6-A, C). Particulate chromate didn’t change the expression of CDK4 in human B lymphoblastoid cells regardless of the exposure time (Fig. 6-B), but the mRNA expression of CDK4 in A549 cells was significantly ($p<0.01$) repressed by moderate and high concentrations of particulate chromate (Fig. 6-D). The mRNA expression of CDK6 in both cell lines was down-regulated by soluble chromate after 24 hours of exposure ($p<0.01$), but no significant change was found in 2-hour exposure groups (Fig. 7-A, C). Also, the mRNA expression of CDK6 in both cell lines was significantly suppressed by 2.5–5.0 μg/cm² of particulate chromate in 24-hour exposure groups ($p<0.01$), and no significant change was observed in 2-hour exposure groups (Fig. 7-B, D).

**The Effects of Cr (VI) on p16 Protein Expression**

The expression change of p16 protein in these two cell lines after being exposed to Cr (VI) for 24 hours was detected by western blotting (Fig. 8). Our results showed that significant ($P<0.05$) increase of p16 protein expression levels was only observed in human B lymphoblastoid cells exposed to 15 μM of K₂Cr₂O₇ and in A549 cells exposed to 5.0 μg/cm² of PbCrO₄.
Discussion

DNA methylation, one of three main types of epigenetic modifications, plays an important role in the regulation of gene expression. Aberrant DNA methylation is believed to be associated with various diseases and developmental disabilities such as cancer and mental retardation, and global hypomethylation and site-specific hypermethylation are common features of human tumors [17,18,19]. Previous studies have demonstrated that Cr (VI) exposure could induce abnormal DNA methylation in Brassica napus L. plants [8], mammalian cells [7,20,21,22], and exposed populations [9,10,23]. Our results indicated that both soluble (K_2Cr_2O_7) and particulate (PbCrO_4) chromate could induce global DNA hypomethylation in human B lymphoblastoid cells and A549 cells, and it was consistent with reports by Wang et al. that chronic occupational chromate exposure also could induce global DNA hypomethylation in chromate manufacturing workers [24]. DNA hypomethylation often targets various genomic

![Figure 4. Detection of DNA methylation status at the promoter of p16 gene by pyrosequencing.](image)

A: Percentages of methylation at the promoter of p16 gene in human B lymphoblastoid cells and in A549 cells exposed to potassium dichromate at the concentrations of 0, 5 μM, 10 μM, and 15 μM for 24 hours. B: Percentages of methylation at the promoter of p16 gene in human B lymphoblastoid cells and in A549 cells exposed to lead chromate at the concentrations of 0, 1.25 μg/cm², 2.5 μg/cm², and 5.0 μg/cm² for 24 hours.

doi:10.1371/journal.pone.0071031.g004

![Figure 5. mRNA expression of p16 gene.](image)

A and C: mRNA expression levels (fold change) of p16 gene in human B lymphoblastoid cells (A) and in A549 cells (C) cells exposed to potassium dichromate at the concentrations of 0, 5 μM, 10 μM, and 15 μM for 2 hours and 24 hours. B and D: mRNA expression levels (fold change) of p16 gene in human B lymphoblastoid cells (B) and in A549 cells (D) cells exposed to lead chromate at the concentrations of 0, 1.25 μg/cm², 2.5 μg/cm², and 5.0 μg/cm² for 4 hours and 24 hours. Asterisks above the bars indicate that the difference between exposure and control was significant (P<0.01).

doi:10.1371/journal.pone.0071031.g005
sequences including repeat sequence, retrotransposons, and CPG poor promoters. It may induce genomic instability, gene activation, and can also disrupt genomic instability [18,25]. Genomic instability paradigm is considered as a possible model for Cr (VI)-induced carcinogenesis, but the specific mechanism remains unclear [3]. Our findings may contribute to investigating its mechanism since global DNA hypomethylation can lead to genomic instability. In addition, we found that the decrease of global DNA methylation levels in 24-hour exposure group was not as obvious as that in short-term (2-hour or 4-hour) exposure group, although it was also statistically significant. This may be due to the fact that DNA methylation change is reversible, and the alteration of DNA methylation status may be just a transient event. Klein et al. [7] also found that exposure time might be a factor affecting the effects of Cr (VI) on methylation in transgenic Chinese Hamster Lung cell line, and they reported that 2-hour exposure to soluble Cr (VI) could result in partial methylation in the gpt gene while 24-hour exposure to particulate chromate induced no methylation changes.

Panayiotidis et al. [26] reported that no changes in global DNA methylation status were observed in A549 cells arrested at either the S- or G2/M-phase of the cell cycle. However, we found decreased global DNA methylation in human B lymphoblastoid cells and A549 cells arrested at G1-phase by Cr (VI). The discrepancy may be due to the different kinds of exposure agents used in these two studies. It can also attribute to the different cell cycle phases arrested in these two experiments. Other previous studies also reported that Cr (VI) could result in cell cycle arrest, but different cells were arrested at different cell phases of cell cycle. For example, Wakeman et al. [27] found that cell cycle was arrested at S-phase in HeLa cells after 10 μM of potassium chromate exposure for 4 hours. Wakeman and Xu [28] reported G1-phase arrest in 293T cells treated with 40 μM of potassium chromate for 4 hours. Zhang et al. [29] observed G2/M phase arrest in human lung epithelial A549 cells exposed to 1 μM – 25 μM of potassium dichromate. Hayashi et al. [30] found that 20 μM of CrO3 could induce G2 phase arrest in U937 and P53 mutated cells after exposure for 24 hours. Our results were consistent with that reported by Stanley et al. [13], and they found that both granulosa cells and spontaneously immortalized rat granulosa cells were arrested at G1 phase after being exposed to 10 μM of potassium dichromate for 24 hours. Therefore, the cellular response of cell cycle arrest to Cr (VI) treatment may be dependent on the types of cells.

Cell cycle progression is regulated by cyclin dependent kinases (CDKs), cyclins, and CDK inhibitors. G1 phase check point is mainly regulated by CDK 4/6, and cyclins D1, D2, and D3, and p16 is a CDK inhibitor targeting CDK 4/6 [31,32]. In the present study, soluble and particulate Cr (VI) inhibited the mRNA expression of CDK4 gene in human B lymphoblastoid cells. It was consistent with the results showed by

Figure 6. mRNA expression of CDK4 gene. A and C: mRNA expression levels (fold change) of CDK4 gene in human B lymphoblastoid cells (A) and in A549 cells (C) cells exposed to potassium dichromate at the concentrations of 0.5 μM, 10 μM, and 15 μM for 2 hours and 24 hours. B and D: mRNA expression levels (fold change) of CDK4 gene in human B lymphoblastoid cells (B) and in A549 cells (D) cells exposed to lead chromate at the concentrations of 0, 1.25 μg/cm², 2.5 μg/cm², and 5.0 μg/cm² for 4 hours and 24 hours. Hash keys above the bars: P<0.05 as compared with control; asterisks above the bars: P<0.01 as compared with control.

doi:10.1371/journal.pone.0071031.g006
Stanley et al. [13] that potassium dichromate significantly decreased protein levels of G1-S phase regulators CDK4 and CDK6 in primary and immortalized granulosa cells, but they didn’t compare the difference of the effects of Cr (VI) on cell cycle arrest between soluble and particulate chromates. The difference of inhibiting effects on CDK 4/6 expression between soluble and particulate chromate might be due to the fact that the up-regulating effect of particulate chromate on CDKs inhibitor p16 was weaker than that of soluble chromate. Thus, Cr (VI) could inhibit both mRNA and protein expressions of CDK4/6 genes, and it may contribute to arresting cell cycle at G1 phase.

Furthermore, we measured the effects of Cr (VI) on mRNA expression of CDK inhibitor p16. p16 is known to inhibit the formation of cyclin D-CDK 4/6 complex and thereby contribute to the G1/S checkpoint response [33]. The results of our study indicated that soluble and particulate chromate could significantly up-regulate mRNA expression of p16, but the up-regulating effect of particulate chromate was weaker than that of soluble chromate in human B lymphoblastoid cells. In addition, slight increase of p16 protein expression was observed in two cell lines after being exposed to the highest concentration of Cr (VI). Elevated expression of p16 is a potent mechanism for inhibiting proliferation, and several distinct stresses, including DNA damage and oncogenic stress, may lead to the enhancement of p16 expression [34]. A number of previous study showed the ability of Cr (VI) to induce DNA damage, and it may be responsible for the elevation of p16 expression. Due to only slight increase of p16 protein was observed in two cell lines after Cr (VI) exposure, p16 might not be physiologically relevant to the growth arrest observed in our study. In addition, we hypothesize that the increased mRNA expression of p16 by Cr (VI) may be associated with changed methylation status at the promoter of this gene. However, our results indicated that p16 gene was completely methylated in both cell lines, and neither soluble nor particulate chromate could change the methylation status of p16 gene, although both of them lowered the global DNA methylation levels of these two cell lines. Therefore, Cr (VI) up-regulated mRNA expression of p16 not through lowering DNA methylation levels at the promoter of this gene, and other mechanisms, such as microRNA and histone modification [5], may be responsible for this up-regulating effect of Cr (VI). Actually, Raynal et al. [35] reported that hypermethylated genes could be reactivated by histone deacetylase inhibitors (HDACi) without any loss in promoter DNA methylation, which showed that DNA methylation did not lock gene expression. Therefore, it is possible that Cr (VI) can up-regulate mRNA expression of p16 through suppressing HDAC expression.

In conclusion, our study suggested that G1 phase cell cycle arrest induced by Cr (VI) may be associated with global hypomethylation in human B lymphoblastoid cells and A549 cells. Cr (VI) could down-regulate mRNA expression of CDK 4/6 genes and up-
regulate mRNA expression of p16 gene, but p16 might be not related to growth arrest for little change in protein expression. In addition, other mechanisms rather than methylation change at the promoter of p16 gene may be involved in up-regulating mRNA expression of p16 gene, and suppression of HDAC expression may be one of them.

**Acknowledgments**

The authors are grateful to Dr Wenzhe Wang, Dr Wei Wu, and Dr Zhengyu Jia for their technical assistance.

**Author Contributions**

Conceived and designed the experiments: JL XZ. Performed the experiments: JL YW LJ XW PS CY MG KL. Analyzed the data: JL YT NW. Contributed reagents/materials/analysis tools: YX YS. Wrote the paper: JL.

**References**

1. Martinez-Zamudio R, Ha HC (2011) Environmental epigenetics in metal exposure. Epigenetics 6: 820–827.
2. Gibb HJ, Lees PS, Pinsky PF, Rooney BC (2000) Lung cancer among workers in chromium chemical production. Am J Ind Med 38: 115–126.
3. Holmes AL, Wise SR, Wise JP Sr. (2000) Carcinogenicity of hexavalent chromium. Indian J Med Res 128: 353–372.
4. Wolff AP, Matzke MA (1999) Epigenetics: regulation through repression. Science 286: 401–406.
5. Choo KR (2011) Epigenetics in disease and cancer. Malays J Pathol 33: 61–70.
6. Rusiecki JA, Baccarelli A, Bollati V, Taranini I, Moore LE, et al. (2008) Global DNA hypomethylation is associated with high serum-persistent organic pollutants in Greenlandic Inuit. Environ Health Perspect 116 Suppl 5: 1547–1552.
7. Klein CB, Su I, Brown D, Leszczynska J. (2002) Chromate-induced epimutations in mammalian cells. Environ Health Perspect 110 Suppl 5: 739–743.
8. Labra M, Grassi F, Imazio S, Di Fabio T, Citterio S, et al. (2004) Genetic and DNA-methylation changes induced by potassium dichromate in Brassica napus L. Chemosphere 54: 1049–1056.
9. Ali AH, Kondo K, Namura T, Saka Y, Takizawa H, et al. (2011) Aberrant DNA methylation of some tumor suppressor genes in lung cancers from workers with chromate exposure. Mol Carcinog 50: 89–99.
10. Kondo K, Takahashi Y, Hirose Y, Nagao T, Tsuyuguchi M, et al. (2006) The reduced expression and aberrant methylation of p16(INK4a) in chromate workers with lung cancer. Lung Cancer 53: 295–302.
11. Chu A, Shi XL, Lee WK, Hill R, Wakeman TP, et al. (2010) Review of chromium (VI) apoptosis, cell-cycle-arrest, and carcinogenesis. J Environ Sci Health C Environ Carcinog Ecotoxicol Rev 28: 188–230.
12. Reynolds M, Arumkocher S, Johnston T, Zhinkovich A (2012) Undetectable role of oxidative DNA damage in cell cycle, cytotoxic and clastogenic effects of Cr(VI) in human lung cells with restored ascorbate levels. Mutagenesis 27: 437–443.

**Figure 8. Protein expression of p16 gene.** Human B lymphoblastoid cells and A549 cells were exposed to potassium dichromate or lead chromate for 24 hours, and p16 protein expression was analyzed by western blot with 100 μg of protein. A–B: Western blots of p16 and tublin in human B lymphoblastoid cells (A) and A549 cells (B). C–D: Histograms of Integrated Density Value for each protein in human B lymphoblastoid cells (C) and A549 cells (D), normalized to tublin. Asterisks above the bars indicate that the difference between exposure and control was significant (P<0.05). doi:10.1371/journal.pone.0071031.g008

**DNA Methylation and Cell Cycle Arrest**

PLOS ONE | www.plosone.org 9 August 2013 | Volume 8 | Issue 8 | e71031
13. Stanley JA, Lee J, Nithy TK, Arosh JA, Burghardt RC, et al. (2011) Chromium-VI arrests cell cycle and decreases granulosa cell proliferation by down-regulating cyclin-dependent kinases (CDK) and cyclins and up-regulating CDK-inhibitors. Reprod Toxicol 32: 112–123.

14. Wise SS, Holmes AE, Wise JP, Sr. (2006) Particulate and soluble hexavalent chromium are cytotoxic and genotoxic to human lung epithelial cells. Mutat Res 610: 2–7.

15. Li, Y, Chen T, Lacerte C, Wise SS, Holmes A, Martino J, et al. (2012) Comparative cytotoxicity and genotoxicity of particulate and soluble hexavalent chromium in human and sperm whale (Physeter macrocephalus) skin cells. Comp Biochem Physiol C Toxicol Pharmacol 155: 143–150.

16. Permenter MG, Levin IA, Jackson DA (2011) Exposure to nickel, chromium, or cadmium causes distinct changes in the gene expression patterns of a rat liver derived cell line. PLoS One 6: e27730.

17. Duthie SJ (2011) Epigenetic modifications and human pathologies: cancer and CVD. Proc Nutr Soc 70: 47–56.

18. Hatzapostolou M, Biopoulo D (2011) Epigenetic aberrations during oncogenesis. Cell Mol Life Sci 68: 1681–1702.

19. Sugawara H, Ishimoto K, Bando M, Ueda J, Ishigoska J, et al. (2011) Comprehensive DNA methylation analysis of human peripheral blood leukocytes and lymphoblastoid cell lines. Epigenetics 6: 508–515.

20. Schneeklother M, Talaska G, Puga A (2007) Chromium cross-links histone deacetylase 1-DNA methyltransferase 1 complexes to chromatin, inhibiting histone-remodeling marks critical for transcriptional activation. Mol Cell Biol 27: 7089–7101.

21. Kondo Y, Shen L, Issa JP (2003) Critical role of histone methylation in tumor suppressor gene silencing in colorectal cancer. Mol Cell Biol 23: 206–215.

22. Sun H, Zhou X, Chen H, Li Q, Costa M (2009) Modulation of histone methylation and MLH1 gene silencing by hexavalent chromium. Toxicol Appl Pharmacol 237: 258–266.

23. Takahashi Y, Kondo K, Hirose T, Nakagawa H, Tsuyuguchi M, et al. (2005) Microsatellite instability and protein expression of the DNA mismatch repair gene, hMLH1, of lung cancer in chromate-exposed workers. Mol Carcinog 42: 150–158.

24. Wang TG, Song YS, Wang H, Zhang J, Yu SF, et al. (2012) Oxidative DNA damage and global DNA hypomethylation are related to folate deficiency in chromate manufacturing workers. J Hazard Mater 213–214: 440–446.

25. Shen X, He Z, Li H, Yao C, Zhang Y, et al. (2012) Distinct functional patterns of gene promoter hypomethylation and hypermethylation in cancer genomes. PLoS One 7: e44822.

26. Panayiotidis MI, Rancourt RG, Pappa A, White CW (2006) Effect of cell cycle growth arrest on global DNA methylation status in human lung epithelial-like (A549) cells. In Vivo 20: 381–386.

27. Wakeman TP, Kins WJ, Callens S, Chua A, Brown KD, et al. (2004) The ATM-SMC1 pathway is essential for activation of the chromium(VI)-induced S-phase checkpoint. Mutat Res 554: 241–251.

28. Wakeman TP, Xu B (2006) ATR regulates hexavalent chromium-induced S-phase checkpoint through phosphorylation of SMC1. Mutat Res 610: 14–20.

29. Zhang Z, Leonard SS, Wang S, Valhathan V, Carstranova V, et al. (2001) Cr(VI) induces cell growth arrest through hydrogen peroxide-mediated reactions. Mol Cell Biochem 222: 77–83.

30. Hayashi K, Kondo T, Zhao QL, Ogawa R, Cui ZG, et al. (2004) Signal transduction of p53-independent apoptotic pathway induced by hexavalent chromium in U937 cells. Toxicol Appl Pharmacol 197: 96–106.

31. Burhans WC, Heinzl NH (2009) The cell cycle is a redox cycle: linking phase-specific targets to cell fate. Free Radic Biol Med 47: 1292–1293.

32. Shackelford RF, Kaufmann WK, Paules RS (2000) Oxidative stress and cell cycle checkpoint function. Free Radic Biol Med 28: 1387–1404.

33. Semczuk A, Jakowicki JA (2004) Alterations of pRb1-cyclin D1-cdk4/6-p16(INK4A) pathway in endometrial carcinogenesis. Cancer Lett 203: 1–12.

34. Winkiewicz AK, Knudsen KE, Dicker AP, Knudsen ES (2011) The meaning of p16(INK4a) expression in tumors: functional significance, clinical associations and future developments. Cell Cycle 10: 2497–2503.

35. Raynal NJ, Si J, Taby RF, Gharibyan V, Ahmed S, et al. (2012) DNA methylation does not stably lock gene expression but instead serves as a molecular mark for gene silencing memory. Cancer Res 72: 1170–1181.